Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $7.75.

A number of brokerages recently commented on PYXS. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. Guggenheim began coverage on shares of Pyxis Oncology in a research note on Wednesday, September 3rd. They issued a “buy” rating and a $5.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Pyxis Oncology in a research note on Tuesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Wednesday, October 8th. Finally, Zacks Research raised shares of Pyxis Oncology from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th.

Pyxis Oncology Stock Down 3.2%

Shares of NASDAQ:PYXS opened at $3.38 on Friday. The company has a market capitalization of $209.62 million, a price-to-earnings ratio of -2.11 and a beta of 1.33. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.39. The firm has a 50 day moving average of $2.21 and a 200 day moving average of $1.51.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. The business had revenue of $2.82 million during the quarter. On average, sell-side analysts expect that Pyxis Oncology will post -1.04 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Large investors have recently made changes to their positions in the business. Catalyst Funds Management Pty Ltd acquired a new position in shares of Pyxis Oncology during the second quarter worth $26,000. Kingstone Capital Partners Texas LLC acquired a new position in shares of Pyxis Oncology during the second quarter worth $37,000. XTX Topco Ltd acquired a new position in shares of Pyxis Oncology during the second quarter worth $40,000. Velan Capital Investment Management LP acquired a new position in shares of Pyxis Oncology during the second quarter worth $44,000. Finally, Bank of America Corp DE increased its position in shares of Pyxis Oncology by 20.3% during the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after purchasing an additional 9,062 shares in the last quarter. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.